-
公开(公告)号:US20140377768A1
公开(公告)日:2014-12-25
申请号:US14374907
申请日:2013-01-28
Applicant: Osaka University
Inventor: Masaru Ishii , Yoshinori Kagawa , Masaki Mori , Hideshi Ishii
IPC: C12N15/113 , C12Q1/68
CPC classification number: C12N15/113 , A61K31/7115 , C12N2310/11 , C12N2310/3231 , C12N2310/3341 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N33/5011 , G01N2333/726 , G01N2500/04 , G01N2800/7028
Abstract: The present invention provides a novel antitumor agent that acts through a novel mechanism. The novel antitumor agent contains as an active ingredient a substance capable of inhibiting a cell cycle-dependent Rho GTPase activating protein (RhoGAP). The RhoGAP is cell cycle-dependent and plays an important role in a process through which cancer cells acquire invasive capacity and/or metastatic capacity. The invasion and/or metastasis of cancer cells can be controlled by targeting the RhoGAP. Examples of the substance capable of inhibiting a cell cycle-dependent RhoGAP include an antisense oligonucleotide against a gene encoding the RhoGAP and an oligonucleotide that induces RNA interference of the gene. As the oligonucleotide, one containing an artificial nucleic acid such as BNA is preferred because of its excellent stability. The present invention also provides a screening method including selecting an antitumor agent capable of suppressing cancer cell invasion and/or metastasis through a novel mechanism. The screening method is a screening method for a novel antitumor agent, including selecting a substance capable of inhibiting a cell cycle-dependent Rho GTPase activating protein.
Abstract translation: 本发明提供一种通过新颖的机理起作用的新型抗肿瘤剂。 新型抗肿瘤剂含有作为活性成分的能够抑制细胞周期依赖性Rho GTPase激活蛋白(RhoGAP)的物质。 RhoGAP是细胞周期依赖性的,并且在癌细胞获得侵袭能力和/或转移能力的过程中起重要作用。 可以通过靶向RhoGAP来控制癌细胞的侵袭和/或转移。 能够抑制细胞周期依赖性RhoGAP的物质的实例包括针对编码RhoGAP的基因的反义寡核苷酸和诱导该基因的RNA干扰的寡核苷酸。 作为寡核苷酸,由于其优异的稳定性,因此优选含有人造核酸如BNA的寡核苷酸。 本发明还提供一种筛选方法,其包括通过新的机理选择能够抑制癌细胞侵袭和/或转移的抗肿瘤剂。 筛选方法是新型抗肿瘤剂的筛选方法,包括选择能够抑制细胞周期依赖性Rho GTPase激活蛋白的物质。
-
公开(公告)号:US20230194472A1
公开(公告)日:2023-06-22
申请号:US17605917
申请日:2020-04-24
Applicant: Osaka University
Inventor: Masateru Taniguchi , Hideshi Ishii , Takahito Ohshiro , Masamitsu Konno
IPC: G01N27/62 , C12Q1/6886
CPC classification number: G01N27/62 , C12Q1/6886
Abstract: The present disclosure provides a method for analyzing a microRNA using a tunneling current. The present disclosure provides a method for identifying the base sequence and/or modification state of a microRNA using a tunneling current, and a system and a program to be used in the method. Furthermore, the present disclosure provides a method for analyzing the conditions of a subject, said method comprising determining the base sequence and/or modification state of a microRNA using a tunneling current. For example, methylation modification can be analyzed thereby.
-
3.
公开(公告)号:US11707530B2
公开(公告)日:2023-07-25
申请号:US16326657
申请日:2017-08-17
Applicant: TOKYO INSTITUTE OF TECHNOLOGY , OSAKA UNIVERSITY
Inventor: Nobuhiro Nishiyama , Hiroyasu Takemoto , Takahiro Nomoto , Keishiro Tomoda , Makoto Matsui , Naoki Yamada , Yuto Honda , Hideshi Ishii , Masaki Mori , Masamitsu Konno
CPC classification number: A61K47/6455 , A61K49/146
Abstract: The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell.
-
公开(公告)号:US20230175066A1
公开(公告)日:2023-06-08
申请号:US16971604
申请日:2019-02-21
Applicant: OSAKA UNIVERSITY
Inventor: Hideshi Ishii , Masamitsu Konno , Masaki Mori
IPC: C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q1/6827 , C12Q2600/106 , C12Q2600/154 , C12Q2600/178
Abstract: The present application provides a novel method for analyzing a biological condition or a medical condition. It is now found that information about the modification of RNA can be used for the analysis of a biological condition or a medical condition. On the basis of this finding, the present invention provides a novel method for analyzing a biological condition or a medical condition. According to the present invention, it becomes possible to analyze various biological conditions or medical conditions including diseases, and it also becomes possible to satisfactorily predict cancer (e.g., pancreatic cancer, colorectal cancer, stomach cancer) in an early stage.
-
5.
公开(公告)号:US20210308271A1
公开(公告)日:2021-10-07
申请号:US16326657
申请日:2017-08-17
Applicant: TOKYO INSTITUTE OF TECHNOLOGY , OSAKA UNIVERSITY
Inventor: Nobuhiro Nishiyama , Hiroyasu Takemoto , Takahiro Nomoto , Keishiro Tomoda , Makoto Matsui , Naoki Yamada , Yuto Honda , Hideshi Ishii , Masaki Mori , Masamitsu Konno
Abstract: The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell.
-
-
-
-